Life Sciences Companies Undergoing Major Technology Shift
CONSHOHOCKEN, Pa., June 26, 2013 /PRNewswire/ -- The life sciences industry is undergoing a major IT platform shift that is transforming the way companies manage their businesses – and that shift is accelerating, according to a survey report released by NextDocs today at the Drug Information Association ( DIA) 2013 Annual Meeting in Boston. The report, The State of SharePoint in Life Sciences, is based on in-depth surveys with more than 100 leading life sciences and pharmaceutical companies, conducted with the aim of better understanding their use of technology to manage regulatory compliance.
"The life sciences industry is experiencing a once-in-a-generation technology platform shift; a shift that is transforming how these companies manage clinical trials, regulatory submissions and manufacturing processes," said Zikria Syed, Chief Executive Officer of NextDocs.
The report reveals that, over the past few years, life sciences companies have dramatically accelerated their shift away from legacy content management systems – and to Microsoft SharePoint for managing regulated content in validated systems. Notably, nearly 37 percent of life sciences companies reported scaling back or replacing their legacy systems, such as EMC Documentum. These companies are shifting towards open-standard platforms; nearly 65 percent say they have already shifted or plan to shift to a Microsoft SharePoint platform.
The survey also reveals a dramatic expansion in use of Microsoft SharePoint to manage strategic aspects of their business, such as the management of regulated content in validated systems, as is required during clinical trials. Four out of ten life sciences companies (43 percent) currently rely on Microsoft SharePoint, along with complimentary solutions, for regulated content management, and another 21 percent are actively planning such a transition.Companies are using Microsoft SharePoint as a platform, often combined with complimentary solutions, for quality management (e.g., CAPA, deviations and change control) (42 percent); managing clinical trial documents (eTMF) (37 percent); and managing documents for FDA submissions (32 percent).
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts